BRIEF published on 02/28/2025 at 07:35, 9 months 5 days ago ABIONYX renforce son engagement contre la Déficience LCAT Autorisation De Mise Sur Le Marché Maladie Rare Déficience LCAT Biomédicament Maladie De Norum
BRIEF published on 02/28/2025 at 07:35, 9 months 5 days ago ABIONYX strengthens its commitment against LCAT Deficiency Rare Disease Marketing Authorization LCAT Deficiency Biomedicine Norum Disease
PRESS RELEASE published on 02/28/2025 at 07:30, 9 months 5 days ago Informations privilégiées / Autres communiqués ABIONYX s’engage dans la Déficience LCAT (Maladie de Norum) en soutenant les patients et préparant l'AMM, bénéficiant de la Désignation de Maladie Orpheline en Europe et aux USA ABIONYX EMA Déficience LCAT Maladie De Norum Désignation Orpheline
PRESS RELEASE published on 02/28/2025 at 07:30, 9 months 5 days ago Inside Information / Other news releases ABIONYX renews commitment to treat LCAT Deficiency (Norum's disease) and provides updates on advances, including submission of Marketing Authorization Application and Orphan Disease Designation ABIONYX LCAT Deficiency Rare Disease Day Marketing Authorization Application Orphan Disease Designation
BRIEF published on 02/27/2025 at 19:25, 9 months 6 days ago ABIONYX Pharma Reports Stable Revenue and Cash Position for 2024 2024 Financial Results Innovative Therapies ABIONYX Pharma Compassionate Access CRO Industry
BRIEF published on 02/27/2025 at 19:25, 9 months 6 days ago ABIONYX Pharma annonce un chiffre d'affaires et une situation de trésorerie stables pour 2024 Résultats Financiers 2024 ABIONYX Pharma Thérapies Innovantes Accès Compassionnel Industrie Des CRO
PRESS RELEASE published on 02/27/2025 at 19:20, 9 months 6 days ago Inside Information / Information on annual revenues ABIONYX Pharma reports €4.6m revenue and €3.2m cash at the end of Q4 2024. Details on business activities and financial performance included Revenue Cash Position Financial Update Biopharma ABIONYX Pharma
PRESS RELEASE published on 02/27/2025 at 19:20, 9 months 6 days ago Informations privilégiées / Information sur chiffre d’affaires annuel ABIONYX Pharma annonce un chiffre d'affaires consolidé de 4,6M€ et une trésorerie de 3,2M€ au 31 décembre 2024 Chiffre D'affaires Trésorerie Biopharma ABIONYX Pharma Thérapies Innovantes
BRIEF published on 02/20/2025 at 07:35, 9 months 13 days ago ABIONYX Pharma reçoit un soutien de 8,7 millions d'euros pour son projet sur le sepsis France 2030 ABIONYX Pharma Sepsis Soutien Financier Biomédicament
BRIEF published on 02/20/2025 at 07:35, 9 months 13 days ago ABIONYX Pharma receives €8.7 million in support for its sepsis project Financial Support France 2030 ABIONYX Pharma Sepsis Biomedicine
Published on 12/05/2025 at 19:20, 27 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 2 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 27 minutes ago NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 1 hour 47 minutes ago SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 2 hours 32 minutes ago TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 18:58, 48 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 1 hour 31 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 2 hours ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 2 hours 29 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 29 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 4 hours 36 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 4 hours 36 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 5 hours 48 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
